“…Previously, we reported the development of a rexinoid called UAB30, which is effective in preventing mammary cancers in rodents while not increasing serum lipids from oral dosing. , In an in vivo mammary cancer prevention model, UAB30 at 200 and 100 mg/kg of diet decreased MNU-initiated cancers by 63 and 29%, respectively, whereas bexarotene orally administered at 150 and 15 mg/kg of diet decreased cancers by 74 and 38%, respectively. ,, Oral dosing of UAB30 in rodents slightly increases serum lipids. Using genomic and proteomic approaches, we demonstrated that unlike bexarotene, UAB30 does not induce the expression of genes in the liver of rodents under the control of the permissive heterodimers that modulate lipid metabolism. , A 28 day oral dosing of UAB30 at multiple doses in normal human volunteers was safely tolerated up to 160 mg daily without any changes in serum lipids or blood chemistry. − Due to its favorable toxicity profile and reasonable potency, UAB30 is currently being evaluated in phase 1b human trials to prevent nonmelanoma skin cancers (NMSCs) in organ transplant patients as well as to prevent other epithelial cancers.…”